Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

A medical expert navigates toxicity management in patients being treated with ribociclib.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

How do you monitor for and manage hematologic toxicities seen with ribociclib?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Nancy Lin, MD | Image Credit: Dana Farber Cancer Institute

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD

ByElla Hohmann, MS,Nancy Lin, MD

June 10th 2026

Iain MacPherson, PhD | Image Credit: UKBCG

Prosigna Scores, Ovarian Suppression, and Chemotherapy Omission: Iain MacPherson, PhD

ByElla Hohmann, MS,Iain MacPherson, PhD

June 8th 2026

Iain MacPherson, PhD | Image Credit: UKBCG

OPTIMA Finds Genomic Test Identifies Who Can Skip Breast Cancer Chemo: Iain MacPherson, PhD

ByElla Hohmann, MS,Iain MacPherson, PhD

June 5th 2026

FDA HQ | Image Credit: Tada Images - stock.adobe.com

5 Notable Oncology FDA Approvals Granted in May

ByBrooke McCormick

June 5th 2026

Mitali Shah, MD | Image Credit: Mitali Shah LinkedIn

Genomic Testing Gaps, Chemotherapy Decisions in Young Women With HR+ Breast Cancer: Mitali Shah, MD

ByElla Hohmann, MS,Mitali Shah, MD

June 4th 2026

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

Shields Health Solutions Partners With Baptist Health on Specialty Pharmacy

AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD